A Phase 2 interventional study of Elafibranor 80mg and Elafibranor 120mg in Non Alcoholic Steatohepatitis, sponsored by Genfit. Terminated at 2 sites in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 414th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 279th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children and adolescent population (8 to 17 years of age) with non alcoholic steatohepatitis (NASH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusion criteria may apply
Exclusion Criteria:
Had clinical and/or historical evidence of cirrhosis, included by not limited to:
Has evidence of chronic liver disease other than NASH, defined by any one of the following:
Other exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
Drug: Elafibranor 80mg
Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
Drug: Elafibranor 120mg
Once daily oral intake of elafibranor 80 mg during 3 months
Also known as: GFT505
Once daily oral intake of elafibranor 120 mg during 3 months
Also known as: GFT505
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Elafibranor and Its Active Metabolite (GFT1007)
Cmax was defined as maximum observed plasma concentration.
Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of Elafibranor and Active Metabolite (GFT1007)
Tmax was defined as time to reach maximum observed plasma concentration.
Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Pharmacokinetics: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Elafibranor and Active Metabolite (GFT1007)
AUC0-24 defined as the area under the plasma concentration versus time curve of the study drug from time 0 to 24 hours.
Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Pharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)
Plasma t1/2 was defined as the time taken by drug to reduce to half of its initial plasma concentration.
Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Pharmacokinetics: Plasma Trough Concentrations (Ctrough) of Elafibranor and Active Metabolite (GFT1007)
Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.
Time frame: Pre-dose on Day 1 and 29
Pharmacodynamics (PD) - Liver Markers: Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), and Alkaline Phosphatase (ALP) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis. Normal range at screening: AST: 0 - 39 international units per liter (IU/L), ALT: 5 - 30 IU/L, GGT: 2 - 24 IU/L, and ALP: 74 - 390 IU/L.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Adiponectin at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Cytokeratin 18 (CK-18)/M65 and CK-18/M30 at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Ferritin at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Hyaluronic Acid, Procollagen 3 N-Terminal Propeptide (PIIINP) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Other Liver Markers: Change From Baseline in Alpha-2 Macroglobulin at Days 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Plasma Glucose (FPG) at Days 15, 29, 57, 85, and 113
Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Days 15, 29, 57, 85, and 113
HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (micro international units per milliliter \[mcIU/mL\]) \* fasting plasma glucose (mmol/L) / 22.5. A higher value indicates a greater insulin resistance. Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Insulin at Days 15, 29, 57, 85, and 113
Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "mIU/L" was abbreviated as "milli-international unit per liter".
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Total Cholesterol (TC) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Non High-density Lipoprotein Cholesterol (Non-HDL-C) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum High-density Lipoprotein Cholesterol (HDL-C) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Low-density Lipoprotein (LDL-C) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Triglycerides at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Calculated Very Low-density Lipoprotein Cholesterol (VLDL-C) at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein A-1 at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein B at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Change From Baseline in Body Weight at Days 15, 29, 57, 85, and 113
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Change From Baseline in Body Mass Index (BMI) Z-Score at Days 15, 29, 57, 85, and 113
The BMI for a given age (in years) and gender (male) was converted to an exact z-score. Given a participant's age, sex, BMI, and an appropriate reference standard, a BMI Z-score was determined. BMI Z-score \>=85th percentile was considered as overweight. Z-score was a statistical measure to describe whether a mean was above or below the standard. A Z-score of 0 was equal to the mean and is considered normal. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Negative values are indicative of decrease in BMI (weight loss) and positive values are indicative of increase in BMI. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Change From Baseline in Waist Circumference at Days 15, 29, 57, 85, and 113
Waist circumference (in centimeters \[cm\]) was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Fibrinogen at Days 29, 57, 85, and 113
Blood samples to assess fibrinogen levels were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Haptoglobin at Days 29, 57, 85, and 113
Blood samples to assess Haptoglobin level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Interleukin-6 at Days 29, 57, 85, and 113
Blood samples to assess Interleukin-6 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Tumor Necrosis Factor Alpha at Days 29, 57, 85, and 113
Blood samples to assess Necrosis Factor Alpha level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 29, 57, 85, and 113
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Plasminogen Activator Inhibitor-1 at Days 29, 57, 85, and 113
Blood samples to assess plasminogen activator inhibitor-1 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "IU/mL" was abbreviated as International units per milliliter.
Time frame: Baseline (Day 1), Day 29, 57, 85, and 113
Pharmacodynamics - Change From Baseline in Pediatric Quality of Life (PedsQL™) (Version 4.0) Generic Core Scales at Day 85
The child, adolescent and parent/legal guardian PedsQL™ (Version 4.0) generic core scales was used to measure health-related quality of life (HRQOL). The response information was completed by the participant and by a parent/legal guardian individually. It consisted of 23 item questionnaire encompassing 4 core scale domains: Physical Functioning (8 items); Emotional Functioning (5 items); Social Functioning (5 items); and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem to 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0), where higher scores indicated better HRQOL. Total Scale Score was the sum of all the items over the number of items answered on all the Scales. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Day 85
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical in a participant or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was another medically important condition. TEAEs were defined as AEs that started prior to first study drug dose and that worsened after, and the AEs that started on or after first study drug dose. TEAEs: Serious and non-serious AEs.
Time frame: From Screening visit (signature of informed consent) up to last dose of study drug + 30 days (i.e., up to Day 113)
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Measurement
ECG measurements were taken with the participants in resting position for at least 10 minutes. The investigator determined whether abnormal assessment results were clinically significant or not. The number of participants with abnormal clinically significant ECG findings were reported. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Day 85
Number of Participants With Abnormal Clinical Chemistry Parameters
Fasting blood samples (collected after 10 hours fasting) were used to assess the following clinical chemistry parameters: creatinine, glomerular filtration rate, creatinine clearance, total proteins, albumin, electrolytes (sodium, potassium, chloride, calcium), uric acid, urea nitrogen, urea, creatine phosphokinase (CPK), AST, ALT, GGT, ALP, total and conjugated bilirubin, high sensitivity C-reactive protein, fasting plasma glucose, fasting insulin, HOMA-IR, fructosamine, C-peptide, free fatty acids, glycated hemoglobin A1c, cystatin C. Abnormal clinical chemistry values were classified based on reference range: lower limit of normality (LLN); normal (\>= LLN and \<= upper limit of normality \[ULN\]); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN. Only the parameters for which at least one value of abnormality were reported and presented in this outcome measure.
Time frame: At Day 85 (i.e., end of treatment)
Number of Participants With Abnormal Hematology and Coagulation Parameters
Fasting blood samples (collected after 10 hours fasting) were used to assess the following hematology and coagulation parameters: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, prothrombin time (PT) and international normalized ratio (INR). Hematology and coagulation values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.
Time frame: At Day 85 (i.e., end of treatment)
Number of Participants With Abnormal Urinalysis Parameters
Blood samples were collected to assess the following urinalysis parameters: alpha-1 macroglobulin, N-acetyl glucosamide, neutrophil gelatinase-associated lipocalin, albumin, and creatinine. Abnormal urinalysis values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.
Time frame: At Day 85 (i.e., end of treatment)
Number of Participants With Abnormal Vital Signs
Vital signs were taken before any invasive procedures. Following vital signs were assessed: systolic blood pressure, diastolic blood pressure, heart rate. Abnormal vita signs was defined as any abnormal findings in the vital sign parameters and were categorized as 'abnormal, not clinically significant (NCS)' and 'abnormal, clinically significant (CS)'.
Time frame: At Day 85 (i.e., end of treatment)
Number of Participants With Clinically Significant Abnormalities in Physical Examination at Baseline, Days 15, 29, 57, 85, and 113
Physical examination findings were collected according to pre-defined body systems: general appearance; skin; eyes; ears; nose; throat; neck and thyroid; lungs; heart; upper/lower extremities; lymph nodes; abdomen; musculoskeletal system; basic neurological assessment. Additional systems were evaluated as needed. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care. Participants with at least one clinically significant abnormality in physical examination were reported and presented in this outcome measure. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113
The study was conducted at 2 centers in the United Sates from 25 June 2019 and 16 June 2020. A total of 27 participants were screened, of which 10 participants were enrolled and randomized (1:1 ratio) to receive elafibranor 80 milligrams (mg)/120 mg sequentially. A total of 17 participants failed screening mainly due to not meeting eligibility criteria.
| Milestone | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
Cmax was defined as maximum observed plasma concentration.
| nanograms per milliliter (ng/mL) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Elafibranor | 385.216 ± 218.646 | 658.054 ± 403.201 |
| GFT1007 | 2367.620 ± 1088.123 | 2875.280 ± 1443.324 |
Tmax was defined as time to reach maximum observed plasma concentration.
| hours | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Elafibranor | 1.50 (0.52 to 2.00) | 1.00 (0.98 to 1.50) |
| GFT1007 | 2.00 (1.50 to 2.00) | 1.50 (1.00 to 1.50) |
AUC0-24 defined as the area under the plasma concentration versus time curve of the study drug from time 0 to 24 hours.
| nanograms*hour per milliliter | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Elafibranor | 973.301 ± 311.803 | 1457.728 ± 724.018 |
| GFT1007 | 10011.405 ± 3575.220 | 10532.930 ± 3257.220 |
Plasma t1/2 was defined as the time taken by drug to reduce to half of its initial plasma concentration.
| hours | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Elafibranor | 34.170 ± NA | 37.620 ± 15.473 |
| GFT1007 | 9.572 ± 5.592 | 6.682 ± 1.120 |
Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.
| ng/mL | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Elafibranor | 14.904 ± 3.516 | 29.035 ± 15.087 |
| GFT1007 | 97.771 ± 49.636 | 55.243 ± 27.769 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis. Normal range at screening: AST: 0 - 39 international units per liter (IU/L), ALT: 5 - 30 IU/L, GGT: 2 - 24 IU/L, and ALP: 74 - 390 IU/L.
| IU/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| ALT: Day 15 | 4.2 ± 21.7 | -13.8 ± 25.0 |
| ALT: Day 29 | -0.2 ± 35.9 | -27.6 ± 18.4 |
| ALT: Day 57 | 0.2 ± 27.3 | -30.8 ± 16.5 |
| ALT: Day 85 | 17.8 ± 56.6 | -34.6 ± 25.6 |
| ALT: Day 113 | 37.3 ± 46.9 | -28.0 ± 22.2 |
| AST: Day 15 | 4.0 ± 16.0 | 0.8 ± 9.5 |
| AST: Day 29 | 4.0 ± 16.3 | -4.0 ± 9.5 |
| AST: Day 57 | 1.0 ± 6.1 | -5.8 ± 4.1 |
| AST: Day 85 | 7.4 ± 15.3 | -8.2 ± 8.3 |
| AST: Day 113 | 9.3 ± 8.4 | -7.8 ± 8.7 |
| GGT: Day 15 | -9.2 ± 6.8 | -8.8 ± 4.4 |
| GGT: Day 29 | -15.6 ± 9.9 | -16.0 ± 5.9 |
| GGT: Day 57 | -1.0 ± 20.7 | -15.6 ± 9.1 |
| GGT: Day 85 | 11.2 ± 39.1 | -16.2 ± 9.9 |
| GGT: Day 113 | 45.3 ± 43.8 | -9.5 ± 6.6 |
| ALP: Day 15 | -4.6 ± 23.1 | -18.0 ± 11.2 |
| ALP: Day 29 | -24.8 ± 28.4 | -14.6 ± 8.1 |
| ALP: Day 57 | -28.2 ± 36.5 | -18.4 ± 8.2 |
| ALP: Day 85 | -32.6 ± 51.5 | -25.0 ± 12.4 |
| ALP: Day 113 | -7.8 ± 45.4 | -16.8 ± 10.2 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| micrograms per milliliter (mcg/mL) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | 0.2410 ± 0.3729 | 0.2112 ± 1.0304 |
| Day 57 | 0.5780 ± 1.0530 | -0.2752 ± 1.0022 |
| Day 85 | 0.3372 ± 1.4844 | -0.0590 ± 1.0476 |
| Day 113 | -0.4663 ± 0.8972 | 0.0322 ± 1.0588 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| IU/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| CK-18/M65: Day 29 | 39.412 ± 346.370 | -70.902 ± 121.905 |
| CK-18/M65: Day 57 | -30.302 ± 326.632 | -60.578 ± 186.165 |
| CK-18/M65: Day 85 | -2.320 ± 231.775 | -122.070 ± 265.059 |
| CK-18/M65: Day 113 | 235.205 ± 290.846 | -188.638 ± 244.324 |
| CK-18/M30: Day 29 | -24.282 ± 374.146 | -68.896 ± 96.850 |
| CK-18/M30: Day 57 | 7.530 ± 445.509 | -20.074 ± 219.782 |
| CK-18/M30: Day 85 | -54.988 ± 315.261 | -81.492 ± 271.506 |
| CK-18/M30: Day 113 | 146.412 ± 273.673 | -170.793 ± 235.722 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| micrograms per liter (mcg/L) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | 6.4 ± 12.0 | 10.8 ± 25.9 |
| Day 57 | 19.4 ± 23.5 | 3.6 ± 15.6 |
| Day 85 | 11.8 ± 16.6 | -4.0 ± 2.4 |
| Day 113 | 6.0 ± 5.7 | -12.8 ± 11.1 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| picograms per milliliter (pg/mL) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Fibroblast Growth Factor 19: Day 29 | -24.4 ± 80.6 | -42.8 ± 78.0 |
| Fibroblast Growth Factor 19: Day 57 | -10.4 ± 51.2 | -18.8 ± 85.3 |
| Fibroblast Growth Factor 19: Day 85 | 28.4 ± 77.5 | -13.0 ± 100.6 |
| Fibroblast Growth Factor 19: Day 113 | -7.8 ± 61.3 | -19.8 ± 35.3 |
| Fibroblast Growth Factor 21: Day 29 | 9.98 ± 91.38 | 128.84 ± 171.50 |
| Fibroblast Growth Factor 21: Day 57 | -36.36 ± 188.91 | 195.94 ± 315.73 |
| Fibroblast Growth Factor 21: Day 85 | 120.68 ± 191.62 | 81.56 ± 130.68 |
| Fibroblast Growth Factor 21: Day 113 | 3.50 ± 291.41 | 56.35 ± 87.53 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| nanograms per milliliter (ng/mL) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Hyaluronic Acid: Day 29 | -2.958 ± 11.689 | -8.800 ± 10.991 |
| Hyaluronic Acid: Day 57 | -0.272 ± 9.228 | -3.654 ± 10.528 |
| Hyaluronic Acid: Day 85 | 4.408 ± 16.612 | -3.518 ± 15.130 |
| Hyaluronic Acid: Day 113 | 1.592 ± 16.445 | -0.422 ± 19.347 |
| Procollagen 3 N-Terminal Propeptide: Day 29 | -3.018 ± 14.079 | -2.878 ± 3.138 |
| Procollagen 3 N-Terminal Propeptide: Day 57 | 1.730 ± 6.928 | -2.762 ± 3.242 |
| Procollagen 3 N-Terminal Propeptide: Day 85 | -1.710 ± 6.730 | -0.470 ± 5.270 |
| Procollagen 3 N-Terminal Propeptide: Day 113 | -7.015 ± 11.902 | -0.530 ± 3.701 |
| Tissue Inhibitor of Metalloproteinase 1: Day 29 | -3.56 ± 25.38 | -8.52 ± 8.98 |
| Tissue Inhibitor of Metalloproteinase 1: Day 57 | 2.80 ± 15.35 | -26.20 ± 32.29 |
| Tissue Inhibitor of Metalloproteinase 1: Day 85 | 16.02 ± 24.84 | -26.26 ± 25.43 |
| Tissue Inhibitor of Metalloproteinase 1: Day 113 | 10.92 ± 21.58 | -31.35 ± 37.95 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.
| gram per liter (g/L) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | -0.098 ± 0.254 | -0.282 ± 0.133 |
| Day 57 | 0.124 ± 0.213 | -0.118 ± 0.064 |
| Day 85 | -0.030 ± 0.328 | -0.204 ± 0.129 |
| Day 113 | -0.105 ± 0.319 | -0.037 ± 0.157 |
Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| millimoles per liter (mmol/L) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 0.22 ± 0.34 | 0.22 ± 0.28 |
| Day 29 | 0.34 ± 0.61 | 0.12 ± 0.47 |
| Day 57 | 0.18 ± 0.58 | 0.10 ± 0.24 |
| Day 85 | 0.28 ± 0.63 | 0.08 ± 0.45 |
| Day 113 | 0.58 ± 0.52 | 0.17 ± 0.35 |
HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (micro international units per milliliter \[mcIU/mL\]) \* fasting plasma glucose (mmol/L) / 22.5. A higher value indicates a greater insulin resistance. Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| Insulin resistance | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 10.720 ± 17.650 | -3.640 ± 5.215 |
| Day 29 | 16.498 ± 43.577 | -4.028 ± 6.512 |
| Day 57 | 4.958 ± 15.472 | -5.448 ± 3.572 |
| Day 85 | 3.742 ± 6.853 | -1.968 ± 7.112 |
| Day 113 | 13.323 ± 22.795 | -4.623 ± 6.883 |
Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "mIU/L" was abbreviated as "milli-international unit per liter".
| mIU/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 30.88 ± 53.53 | -15.66 ± 20.92 |
| Day 29 | 40.12 ± 116.20 | -16.76 ± 24.12 |
| Day 57 | 12.42 ± 41.76 | -23.10 ± 12.58 |
| Day 85 | 9.70 ± 15.49 | -7.48 ± 26.76 |
| Day 113 | 34.15 ± 58.20 | -19.57 ± 25.56 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.070 ± 0.440 | -0.328 ± 0.230 |
| Day 29 | -0.356 ± 0.252 | -0.288 ± 0.347 |
| Day 57 | 0.380 ± 0.565 | -0.286 ± 0.129 |
| Day 85 | 0.298 ± 0.836 | -0.274 ± 0.306 |
| Day 113 | 0.665 ± 0.919 | 0.105 ± 0.270 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.134 ± 0.414 | -0.348 ± 0.163 |
| Day 29 | -0.324 ± 0.196 | -0.316 ± 0.432 |
| Day 57 | 0.368 ± 0.340 | -0.316 ± 0.194 |
| Day 85 | 0.156 ± 0.615 | -0.420 ± 0.290 |
| Day 113 | 0.605 ± 0.714 | -0.038 ± 0.229 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 0.060 ± 0.068 | 0.020 ± 0.223 |
| Day 29 | -0.032 ± 0.124 | 0.032 ± 0.137 |
| Day 57 | 0.008 ± 0.228 | 0.030 ± 0.168 |
| Day 85 | 0.138 ± 0.278 | 0.150 ± 0.191 |
| Day 113 | 0.065 ± 0.259 | 0.150 ± 0.047 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.224 ± 0.365 | -0.084 ± 0.213 |
| Day 29 | -0.344 ± 0.184 | -0.076 ± 0.355 |
| Day 57 | 0.314 ± 0.355 | -0.038 ± 0.078 |
| Day 85 | 0.080 ± 0.686 | -0.184 ± 0.223 |
| Day 113 | 0.385 ± 0.691 | 0.108 ± 0.134 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 0.200 ± 0.363 | -0.576 ± 0.442 |
| Day 29 | 0.042 ± 0.214 | -0.530 ± 0.385 |
| Day 57 | 0.124 ± 0.326 | -0.606 ± 0.384 |
| Day 85 | 0.170 ± 0.389 | -0.532 ± 0.399 |
| Day 113 | 0.485 ± 0.918 | -0.315 ± 0.353 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 0.086 ± 0.172 | -0.270 ± 0.200 |
| Day 29 | 0.018 ± 0.103 | -0.244 ± 0.168 |
| Day 57 | 0.052 ± 0.140 | -0.282 ± 0.176 |
| Day 85 | 0.072 ± 0.168 | -0.240 ± 0.176 |
| Day 113 | 0.215 ± 0.419 | -0.153 ± 0.156 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| grams per liter (g/L) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | 0.112 ± 0.129 | -0.058 ± 0.149 |
| Day 29 | 0.012 ± 0.139 | -0.058 ± 0.144 |
| Day 57 | 0.108 ± 0.211 | -0.060 ± 0.176 |
| Day 85 | 0.128 ± 0.268 | 0.016 ± 0.160 |
| Day 113 | 0.103 ± 0.313 | 0.048 ± 0.060 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| g/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.058 ± 0.064 | -0.082 ± 0.074 |
| Day 29 | -0.098 ± 0.081 | -0.078 ± 0.097 |
| Day 57 | 0.066 ± 0.092 | -0.062 ± 0.086 |
| Day 85 | 0.020 ± 0.189 | -0.036 ± 0.090 |
| Day 113 | 0.117 ± 0.209 | -0.005 ± 0.135 |
Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| kilograms (kg) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.08 ± 3.03 | -0.92 ± 1.70 |
| Day 29 | -0.32 ± 4.54 | -0.98 ± 2.06 |
| Day 57 | 0.73 ± 5.18 | -0.68 ± 3.27 |
| Day 85 | 1.54 ± 5.42 | 0.24 ± 4.07 |
| Day 113 | 4.40 ± 3.05 | 0.73 ± 4.63 |
The BMI for a given age (in years) and gender (male) was converted to an exact z-score. Given a participant's age, sex, BMI, and an appropriate reference standard, a BMI Z-score was determined. BMI Z-score \>=85th percentile was considered as overweight. Z-score was a statistical measure to describe whether a mean was above or below the standard. A Z-score of 0 was equal to the mean and is considered normal. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Negative values are indicative of decrease in BMI (weight loss) and positive values are indicative of increase in BMI. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| Z-Score | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -0.064 ± 0.146 | -0.054 ± 0.095 |
| Day 29 | -0.091 ± 0.247 | -0.054 ± 0.110 |
| Day 57 | -0.108 ± 0.284 | -0.058 ± 0.162 |
| Day 85 | -0.074 ± 0.290 | -0.026 ± 0.197 |
| Day 113 | 0.068 ± 0.116 | 0.022 ± 0.247 |
Waist circumference (in centimeters \[cm\]) was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| cm | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 15 | -1.056 ± 2.953 | -0.998 ± 2.961 |
| Day 29 | -0.656 ± 3.654 | -2.010 ± 2.625 |
| Day 57 | -0.316 ± 3.520 | -2.054 ± 4.106 |
| Day 85 | 0.252 ± 3.379 | -1.346 ± 3.894 |
| Day 113 | 1.625 ± 2.394 | -0.580 ± 4.099 |
Blood samples to assess fibrinogen levels were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| micromoles per liter (mcmol/L) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | -1.450 ± 1.265 | -2.474 ± 1.418 |
| Day 57 | -0.524 ± 1.309 | -2.220 ± 0.756 |
| Day 85 | -1.340 ± 1.492 | -1.748 ± 1.000 |
| Day 113 | -0.295 ± 1.936 | -1.150 ± 1.841 |
Blood samples to assess Haptoglobin level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| g/L | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | -0.086 ± 0.102 | -0.350 ± 0.244 |
| Day 57 | 0.068 ± 0.118 | -0.300 ± 0.209 |
| Day 85 | 0.066 ± 0.077 | -0.298 ± 0.236 |
| Day 113 | 0.178 ± 0.208 | -0.058 ± 0.081 |
Blood samples to assess Interleukin-6 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| picograms per milliliter (pg/mL) | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | 0.036 ± 0.080 | 0.142 ± 0.751 |
| Day 57 | 0.100 ± 0.224 | -0.092 ± 1.096 |
| Day 85 | 0.142 ± 0.243 | 0.062 ± 0.809 |
| Day 113 | 0.143 ± 0.285 | 0.078 ± 0.534 |
Blood samples to assess Necrosis Factor Alpha level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| pg/mL | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | -0.134 ± 0.437 | -0.460 ± 0.857 |
| Day 57 | 0.068 ± 0.388 | -0.270 ± 0.651 |
| Day 85 | -0.068 ± 0.416 | -0.622 ± 0.939 |
| Day 113 | 0.163 ± 0.534 | -0.445 ± 0.988 |
Blood samples to assess plasminogen activator inhibitor-1 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "IU/mL" was abbreviated as International units per milliliter.
| IU/mL | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Day 29 | -8.95 ± 14.19 | -1.40 ± 10.33 |
| Day 57 | 9.68 ± 32.87 | 2.46 ± 15.03 |
| Day 85 | -2.43 ± 7.57 | 2.62 ± 23.77 |
| Day 113 | 5.75 ± 26.71 | 5.40 ± 5.42 |
The child, adolescent and parent/legal guardian PedsQL™ (Version 4.0) generic core scales was used to measure health-related quality of life (HRQOL). The response information was completed by the participant and by a parent/legal guardian individually. It consisted of 23 item questionnaire encompassing 4 core scale domains: Physical Functioning (8 items); Emotional Functioning (5 items); Social Functioning (5 items); and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem to 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0), where higher scores indicated better HRQOL. Total Scale Score was the sum of all the items over the number of items answered on all the Scales. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| units on a scale | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Parent | -3.80 ± 13.76 | -13.04 ± 11.32 |
| Participants | -3.04 ± 1.42 | -3.04 ± 9.01 |
An adverse event (AE) was any untoward medical in a participant or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was another medically important condition. TEAEs were defined as AEs that started prior to first study drug dose and that worsened after, and the AEs that started on or after first study drug dose. TEAEs: Serious and non-serious AEs.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Participants with TEAEs | 2 | 0 |
| Participants with Serious TEAEs | 0 | 0 |
ECG measurements were taken with the participants in resting position for at least 10 minutes. The investigator determined whether abnormal assessment results were clinically significant or not. The number of participants with abnormal clinically significant ECG findings were reported. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Baseline (Day1): Abnormal, clinically significant | 0 | 0 |
| Day 85: Abnormal, clinically significant | 0 | 0 |
Fasting blood samples (collected after 10 hours fasting) were used to assess the following clinical chemistry parameters: creatinine, glomerular filtration rate, creatinine clearance, total proteins, albumin, electrolytes (sodium, potassium, chloride, calcium), uric acid, urea nitrogen, urea, creatine phosphokinase (CPK), AST, ALT, GGT, ALP, total and conjugated bilirubin, high sensitivity C-reactive protein, fasting plasma glucose, fasting insulin, HOMA-IR, fructosamine, C-peptide, free fatty acids, glycated hemoglobin A1c, cystatin C. Abnormal clinical chemistry values were classified based on reference range: lower limit of normality (LLN); normal (\>= LLN and \<= upper limit of normality \[ULN\]); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN. Only the parameters for which at least one value of abnormality were reported and presented in this outcome measure.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Total proteins: >ULN and <3 ULN | 1 | 1 |
| Albumin: >ULN and <3 ULN | 1 | 0 |
| CPK: >ULN and <3 ULN | 0 | 1 |
| AST: >ULN and <3 ULN | 3 | 0 |
| ALT: >ULN and <3 ULN | 3 | 4 |
| ALT: >=3 ULN and <5 ULN | 1 | 0 |
| ALT: >=5 ULN | 1 | 0 |
| GGT: >ULN and <3 ULN | 2 | 2 |
| GGT: >=3 ULN and <5 ULN | 1 | 0 |
| GGT: >=5 ULN | 1 | 0 |
| ALP: >ULN and <3 ULN | 1 | 0 |
| Total Bilirubin: >ULN and <3 ULN | 0 | 1 |
| Conjugated Bilirubin: >ULN and <3 ULN | 0 | 1 |
| C Reactive Protein: >ULN and <3 ULN | 0 | 1 |
| Fasting plasma glucose: >ULN and <3 ULN | 1 | 0 |
| Fasting insulin: >ULN and <3 ULN | 3 | 5 |
| Fasting insulin: >=3 ULN and <5 ULN | 2 | 0 |
| C-peptide: >ULN and <3 ULN | 4 | 2 |
| Hemoglobin A1C: >ULN and <3 ULN | 1 | 0 |
Fasting blood samples (collected after 10 hours fasting) were used to assess the following hematology and coagulation parameters: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, prothrombin time (PT) and international normalized ratio (INR). Hematology and coagulation values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Haemoglobin: >ULN and <3 ULN | 0 | 0 |
| Hematocrit: >ULN and <3 ULN | 0 | 0 |
| RBC: >ULN and <3 ULN | 0 | 1 |
| WBC: >ULN and <3 ULN | 0 | 0 |
| Neutrophils: >ULN and <3 ULN | 0 | 0 |
| Eosinophils: >ULN and <3 ULN | 0 | 0 |
| Basophils: >ULN and <3 ULN | 0 | 0 |
| Lymphocytes: >ULN and <3 ULN | 0 | 0 |
| Monocytes: >ULN and <3 ULN | 0 | 0 |
| Platelets: >ULN and <3 ULN | 0 | 0 |
| PT: >ULN and <3 ULN | 0 | 0 |
| INR: >ULN and <3 ULN | 0 | 0 |
Blood samples were collected to assess the following urinalysis parameters: alpha-1 macroglobulin, N-acetyl glucosamide, neutrophil gelatinase-associated lipocalin, albumin, and creatinine. Abnormal urinalysis values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Alpha-1 Microglobulin: >ULN and <3 ULN | 0 | 0 |
| N-Acetyl Glucosamide: >ULN and <3 ULN | 0 | 0 |
| Neutrophil Gelatinase-associated: >ULN and <3 ULN | 0 | 0 |
| Albumin: : >ULN and <3 ULN | 0 | 0 |
| Creatinine | 0 | 0 |
Vital signs were taken before any invasive procedures. Following vital signs were assessed: systolic blood pressure, diastolic blood pressure, heart rate. Abnormal vita signs was defined as any abnormal findings in the vital sign parameters and were categorized as 'abnormal, not clinically significant (NCS)' and 'abnormal, clinically significant (CS)'.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Systolic Blood Pressure:Abnormal, not clinically significant | 0 | 0 |
| Systolic Blood Pressure: Abnormal, clinically significant | 0 | 0 |
| Diastolic Blood Pressure: Abnormal, not clinically significant | 0 | 0 |
| Diastolic Blood Pressure: Abnormal, clinically significant | 0 | 0 |
| Heart Rate: Abnormal, not clinically significant | 0 | 0 |
| Heart Rate: Abnormal, clinically significant | 0 | 0 |
Physical examination findings were collected according to pre-defined body systems: general appearance; skin; eyes; ears; nose; throat; neck and thyroid; lungs; heart; upper/lower extremities; lymph nodes; abdomen; musculoskeletal system; basic neurological assessment. Additional systems were evaluated as needed. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care. Participants with at least one clinically significant abnormality in physical examination were reported and presented in this outcome measure. Baseline was defined as the last measurement before first intake of study treatment on Day 1.
| Participants | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| Baseline (Day 1) | 4 | 2 |
| Day 15 | 0 | 0 |
| Day 29 | 1 | 0 |
| Day 57 | 0 | 0 |
| Day 85 | 0 | 0 |
| Day 113 | 0 | 0 |
Collected over All AEs were collected from screening through 30 days after last dose of study drug (i.e., up to Day 113) regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elafibranor 80 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Elafibranor 120 mg | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Elafibranor 80 mg | Elafibranor 120 mg |
|---|---|---|
| HepatomegalyHepatobiliary disorders | 1/5 | 0/5 |
| Gastroenteritis viralInfections and infestations | 1/5 | 0/5 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/5 | 0/5 |
Analysis was performed on intent-to-treat (ITT) population that had included participants who were randomized and had received at least 1 dose of the study drug.
| Age, Continuous(years) | Elafibranor 80 mg | Elafibranor 120 mg | Total |
|---|---|---|---|
| Mean | 14.52 ± 2.23 | 15.70 ± 2.31 | 15.11 ± 2.23 |
| Sex: Female, Male(Participants) | Elafibranor 80 mg | Elafibranor 120 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Elafibranor 80 mg | Elafibranor 120 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Elafibranor 80 mg | Elafibranor 120 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 2 | 3 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2019 to primary completion in Jun 2020, 11 months.
Results were first posted in Oct 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor
Non-alcoholic Fatty Liver Disease →